Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

One-time gene therapy Zolgensma from Novartis shows lasting benefits for SMA patients

By Brian Buntz | March 20, 2023

Zolgensma

[Zolgensma image from Novartis]

A gene therapy for spinal muscular atrophy (SMA) patients is making waves. Novartis (NYSE:NVS) revealed in a press release new long-term data highlighting the durability of Zolgensma (onasemnogene abeparvovec) up to 7.5 years after a single treatment. The data comes from two long-term follow-up studies, LT-001 and LT-002, which examined a range of patient populations and demonstrated a positive overall benefit-risk profile. LT-001 is an ongoing 15-year long-term follow-up study of patients who completed the phase 1  START study. More than 3,000 children have been treated with Zolgensma in clinical trials, managed access programs and commercial settings.  Novartis expects Zolgensma to eventually generate $1.5–2 billion, according to BioPharma Dive. NVS shares were up 1 percent to $83.01 today after announcing the new data.  FDA approved Zolgensma (onasemnogene abeparvovec-xioi) in 2019 for children less than two years old with SMA. At that time, it was the most expensive drug to win FDA approval with a price of more than $2 million.

Study Cohort Total Patients Mean Age Mean Follow-up Time Patients Maintaining Milestones Add-on Therapy TEAEs
LT-001 Therapeutic Dose 10 7.1 6.86 100% 60% 0%
LT-002 IV Cohort 63 3.7 3.4 100% 62% 31.7%
LT-002 IT Cohort 18 5.3 3.6 100% 50% 11.1%
Key: IV: Intravenous, IT: Intrathecal, TEAEs: Treatment-emergent adverse events

 

The posters on the two studies highlighted below are available at the following links:

  • LT-001.
  • LT-002.

Comparing SMA treatments and therapies for similar conditions

In the context of other gene therapies for spinal muscular atrophy or similar conditions, Biogen’s (Nasdaq:BIIB) Spinraza (nusinersen) is an FDA-approved treatment for SMA. Although not a gene therapy, it is an antisense oligonucleotide that helps improve motor function in SMA patients through a series of regular spinal injections. Another promising gene therapy is SRK-015 by Scholar Rock (Nasdaq:SRRK), currently in clinical development to treat SMA patients by promoting muscle growth. For other similar conditions, such as Duchenne muscular dystrophy (DMD), several gene therapies are in development, like Sarepta Therapeutics’ (Nasdaq:SRPT) SRP-9001, which is currently in clinical trials. Solid Biosciences (Nasdaq:SLDB) is also developing SGT-001, a gene therapy for DMD patients that aims to restore dystrophin expression and improve muscle function.

The future of gene therapy in treating SMA

The data emphasizes the potential of Zolgensma, with patients in the LT-001 study maintaining all previously achieved motor milestones up to 7.5 years after treatment. Some patients even gained new milestones, such as standing with assistance, during the long-term follow-up period. Novartis’ latest data highlights the potential of gene therapy in treating SMA patients, paving the way for more patients to receive the treatment. As the number of gene therapy recipients increases worldwide, Novartis is committed to expanding access to Zolgensma, offering hope and improved quality of life to SMA patients and their families. The success of Zolgensma may also help drive further research and development of gene therapies for other neuromuscular disorders, providing a new treatment paradigm for these devastating conditions.


Filed Under: Cell & gene therapy
Tagged With: benefit-risk profile, clinical trials, gene therapy, long-term data, Novartis, patient populations, SMA, spinal muscular atrophy, Zolgensma
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid prep to 5 minutes hands-on
Can space help heal hearts? ISS study charts new path for stem cell therapy
MIT team designs gene circuits for tighter control in gene therapy study
Meet STITCHR, the retrotransposon-based gene editor that enables large, scarless DNA insertions
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE